adherence - Page 1 | CARLAT PUBLISHING

Clinical Update

A Clinician’s Guide to Drug Courts

July 1, 2024

Stephen Wemakor, MD and Noah Capurso, MD

Stephen Wemakor, MD, Department of Psychiatry, Yale University, New Haven, CT; Noah Capurso, MD, MHS, Assistant Professor of Psychiatry, Yale University, & Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Wemakor and Capurso have no financial relationships with companies related to this material.

Many of your patients with substance use disorders will become involved with the legal system over the course of their work with you, and one of the most common avenues is through the drug
court system. Here, we provide the basics of how drug courts function and review how best to work with these courts when they request information.

Research Update

Surprise Result for Adherence in Bipolar Disorder

November 9, 2023

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Lithium’s reputation as a difficult med may have more to do with branding than reality, according to this large analysis of mood stabilizer adherence.

CLINICAL UPDATE

The Psychodynamics of Psychopharmacology: Reimagining the “Med Check”

September 12, 2023

Ronald Pies, M.D.

Ronald W. Pies, MD. Professor Emeritus of Psychiatry and Lecturer on Bioethics and Humanities, SUNY Upstate Medical University; Professor Emeritus of Psychiatry, Tufts University School of Medicine; and Editor-in-Chief Emeritus of Psychiatric Times.

Dr. Pies has no financial relationships with companies related to this material.

The role of unconscious psychodynamic factors, the therapeutic alliance, and the transitional object in shaping medication adherence and treatment outcomes.

Can Antidepressants Prolong Survival in Cancer Patients?

May 21, 2021

Paul Barkopoulos, MD.

Paul Barkopoulos, MD. Dr. Barkopoulos has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Antidepressant adherence is linked with increased survival among cancer patients.

Can Assertive Treatment Improve Treatment Adherence in Young Adults With Opioid Use Disorder?

December 10, 2020

Deepti Anbarasan, MD.

Deepti Anbarasan, MD. Dr. Anbarasan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Adherence may often limit effectiveness of medications for opioid use disorder among youth. In this randomized controlled trial, young adults with opioid use disorder were randomized to either youth opioid recovery support (an assertive intervention designed to increase adherence) or treatment as usual, both involving extended-release naltrexone.